<SEC-DOCUMENT>0001571049-14-003916.txt : 20140812
<SEC-HEADER>0001571049-14-003916.hdr.sgml : 20140812
<ACCEPTANCE-DATETIME>20140812161708
ACCESSION NUMBER:		0001571049-14-003916
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20140812
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140812
DATE AS OF CHANGE:		20140812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		141034157

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1401539_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): August 12, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 28%; font-weight: bold; text-align: center">Delaware</TD><TD STYLE="width: 8%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 28%; font-weight: bold; text-align: center">0-50626</TD><TD STYLE="width: 8%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 28%; font-weight: bold; text-align: center">91-1707622</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">(State or other jurisdiction</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">(Commission File Number)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">(IRS Employer</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">of incorporation)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Identification No.)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>200 Connell Drive, Suite 1500</B><BR>
<B>Berkeley Heights, NJ 07922 </B><BR>
<B>(Address of principal executive offices and zip code) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 75%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-size: 10pt"><B>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-size: 10pt"><B>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02 Results of Operations and Financial Condition.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left">The information set forth under this &ldquo;Item
2.02. Results of Operations and Financial Condition,&rdquo; including the exhibit attached hereto, shall not be deemed &ldquo;filed&rdquo;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference
into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such
filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left">Attached as Exhibit 99.1 is a copy of a
press release of Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;), dated August 12, 2014, announcing certain financial
results for the second quarter ended June 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company will conduct a conference call
to review its financial results on August 12, 2014, at 4:30 p.m., Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt"><B>Exhibit</B><BR>
    <B>Number</B></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 10%; font-size: 10pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 89%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Press release announcing financial results for the second quarter ended June 30, 2014, dated August 12, 2014.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 7%; font-size: 10pt"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 41%; border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance, </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 12, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1401539_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="logo.jpg" ALT=""></td>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: right; vertical-align: middle"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cyclacel
    Pharmaceuticals, Inc.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="logo1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS REPORTS SECOND
QUARTER 2014 FINANCIAL RESULTS&#9;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&mdash; Conference Call Scheduled
August 12, 2014 at 4:30 p.m. EDT &mdash;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Berkeley Heights, NJ, August 12, 2014
</B>- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot; or the &quot;Company&quot;), a biopharmaceutical
company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious
disorders, today reported its financial results and business highlights for the second quarter ended June 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s net loss applicable
to common shareholders for the second quarter ended June 30, 2014 was $4.9 million, or $0.22 per basic and diluted share, compared
to net income applicable to common shareholders of $1.4 million, or $0.10 per basic and diluted share, which included a non-routine
income item of $5.5 million, for the second quarter ended June 30, 2013. As of June 30, 2014, cash and cash equivalents totaled
$33.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&ldquo;We are
pleased to report that we have enrolled over 70% of the required number of patients in our Phase 3 SEAMLESS trial in front-line
AML. At present we have approximately 90 study centers open for enrollment in the US and Europe with additional sites to be added,&quot;
said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. &quot;We expect to complete SEAMLESS enrollment around
the end of 2014 with data readout in the second half of 2015. Having surpassed enrollment of 300 patients, we expect the study's
Data Safety Monitoring Board (DSMB) to perform the fourth periodic safety review once 60 days of follow-up have been observed.
The next DSMB review will be an interim analysis for futility and will occur after 212 events have been observed. As indicated
previously, SEAMLESS is funded to completion. Following Phase 2 data for sapacitabine reported at ASH 2013, demonstrating a near
doubling of expected median survival of older patients with MDS after treatment failure of hypomethylating agents, we disclosed
during ASCO 2014 our proposed randomized, controlled trial design in this underserved patient population. We are currently conducting
assessment of feasibility for this study and will provide further information once the findings become available.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Sapacitabine
in SEAMLESS, pivotal, Phase 3 study for first-line treatment in elderly patients with acute myeloid leukemia (AML): </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Study
                                         enrollment is over 70% of the required patients from mostly US clinical sites</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         90 sites open in the US and Europe; with additional sites to be activated</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Surpassing
                                         300 patients enrolled triggers fourth safety review by the DSMB</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Sapacitabine
for patients with myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Disclosed
                                         proposed study design for eligible patients aged 60 years or older with intermediate-2
                                         or high-risk MDS who have failed prior hypomethylating agent therapy</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.45pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings">&thorn;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">200
                                         Connell Drive, Suite 1500, Berkeley Heights, NJ&nbsp; 07922 USA T: +1 (908) 517 7330
                                         F: +1 (866) 271 3466 </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.45pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Dundee
                                         Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382
                                         206 067</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>www.cyclacel.com</U> &ndash; <U>info@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         250 patients will be enrolled in a Phase 2b randomized, controlled trial (RCT) with a
                                         lead-in stage</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Feasibility
                                         assessment is in progress</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Other Events</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Closed
                                         an underwritten offering for net proceeds for approximately $9.3 million after deduction
                                         of offering expenses </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Second Quarter
2014 Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Grant Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue for the three months ended June
30, 2014, was $0.4 million compared to $0.3 million for the same period of the previous year. The revenue is related to previously
awarded grants from the UK government being recognized over the period to progress CYC065, a Cyclin Dependent Kinase inhibitor,
to IND and to complete IND-directed preclinical development of CYC140, a novel, orally available, Polo-Like Kinase 1 (PLK 1) inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased
to $4.5 million for the three months ended June 30, 2014, compared to $2.6 million for the same period in the previous year. The
increase was primarily due to study and site startup costs associated with the expansion of the SEAMLESS registration study into
Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses for
the three months ended June 30, 2014 decreased to $1.4 million compared to $1.8 million for the same period in 2013. The decrease
was primarily due to higher legal and professional fees during the three months ended June 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cyclacel&rsquo;s Key Milestones for
2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 25.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sapacitabine
                                         in SEAMLESS:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">DSMB
                                         safety review of approximately 300 patients enrolled with 60-day follow-up</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">DSMB
                                         review of SEAMLESS data for futility once 212 events have been observed</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Completion
                                         of SEAMLESS enrollment </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 25.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sapacitabine
                                         in MDS:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Complete
                                         feasibility assessment of proposed RCT </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 25.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sapacitabine
                                         in solid tumors:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Report
                                         updated Phase 1 sapacitabine and seliciclib combination data in patients with solid tumors
                                         including those carrying gBRCA mutations</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 25.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Advance
                                         early pipeline</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 43.5pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conference call and Webcast Information:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cyclacel will conduct a conference call
on August 12, 2014 at 4:30&nbsp;p.m. Eastern Time to review the second quarter 2014 results. Conference call and webcast details
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conference call information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">US/Canada call: (877) 493-9121/ international
call: (973) 582-2750</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">US/Canada archive: (800) 585-8367 / international
archive: (404) 537-3406</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Code for live and archived conference
call is 77500832</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the live and archived webcast, please
visit the Corporate Presentations and Events page on the Cyclacel website at <U>www.cyclacel.com</U>. The webcast will be archived
for 90 days and the audio replay for 7 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cyclacel is a biopharmaceutical company
developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.
Sapacitabine, Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial being conducted under an
SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies for myelodysplastic
syndromes (MDS), chronic lymphocytic leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic cancer and
in particular those carrying gBRCA mutations.&nbsp;Cyclacel's strategy is to build a diversified biopharmaceutical business focused
in hematology and oncology based on a development pipeline of novel drug candidates. Please visit <U>www.cyclacel.com</U> for
additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and
results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical
trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners
for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that
include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;believes,&quot;
&quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot;
&quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot; &quot;goal,&quot; or the negative of those
words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties
the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with
the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information,
future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts for Cyclacel Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company: Paul McBarron, (908) 517-7330,
<U>pmcbarron@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations: Russo Partners LLC,
Robert Flamm, (212) 845-4226, <U>robert.flamm@russopartnersllc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&copy; Copyright 2014 Cyclacel Pharmaceuticals,
Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CYCLACEL PHARMACEUTICALS, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In $000s, except share and per share
amounts)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Three&nbsp;Months&nbsp;Ended</FONT><BR>
    <FONT STYLE="font-size: 8pt">June 30,</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2013</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Grant revenue</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">264</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">356</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">264</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">356</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,631</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,545</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,787</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,386</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total operating
    expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,418</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,931</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Operating loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,154</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,575</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Change in valuation of financial instruments associated
    with stock purchase agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(64</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Change in valuation of liabilities measured at fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Foreign exchange&nbsp;&nbsp;losses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(101</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Other income, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total other income (expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,402</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(60</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Income (loss) from continuing operations
    before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,248</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,635</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Income tax benefit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">230</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">816</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Net income (loss) from continuing
    operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,478</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,819</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Discontinued operations:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Income from discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Income tax on discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net income from
    discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Net income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,812</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Deemed dividend on convertible exchangeable preferred
    shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Dividend on convertible exchangeable
    preferred shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(63</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net income
    (loss) applicable to common shareholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,429</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,862</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Basic earnings per common share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0">Net income (loss) per share, continuing operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net income (loss) per share, discontinued
    operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net income (loss) per share applicable
    to common shareholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Diluted earnings per common share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0">Net income (loss) per share, continuing operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net income (loss) per share, discontinued
    operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net income (loss) per share applicable
    to common shareholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Weighted average shares of common stock outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,885,442</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,582,283</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,927,371</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,582,283</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CYCLACEL PHARMACEUTICALS, INC.<BR>
CONDENSED CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In $000s, except share, per share,
and liquidation preference amounts)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">December 31,</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">June 30,</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">2013</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">(Unaudited)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">31,146</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">33,456</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,388</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,422</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Current assets of discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">639</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">403</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,281</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Property and equipment (net)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">305</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Long-term assets of discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">72</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35,520</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">37,610</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,543</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accrued and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,431</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,095</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Other liabilities measured at fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Current liabilities of discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">260</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">145</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,256</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,783</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">241</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">238</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,497</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,021</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Preferred stock, $0.001 par value; 5,000,000 shares
    authorized at December&nbsp;31, 2013 and&nbsp;June 30, 2014; 335,273 shares issued and outstanding at December&nbsp;31, 2013
    and June 30, 2014.&nbsp;Aggregate preference in liquidation of $3,989,749 at December&nbsp;31, 2013 and June 30, 2014.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Common stock, $0.001 par value; 100,000,000 shares
    authorized at December&nbsp;31, 2013&nbsp;and&nbsp;June 30, 2014; 19,369,332 and 22,676,475 shares issued and outstanding
    at December&nbsp;31,&nbsp;2013 and June 30, 2014, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">317,543</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">328,774</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accumulated other comprehensive income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(109</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(97</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(289,430</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(299,111</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28,023</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">29,589</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35,520</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">37,610</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SOURCE: Cyclacel Pharmaceuticals, Inc.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</body>
</Html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1`"U`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`W^/?NO=!'W7WKU5\>-C5_8G;N[\=M';5#>*&2K9ILCF,
M@49X,/@,33K)D,UEZK3Z(((W:UV;2BLP$O*G*',7.V[ILG+5L]S?OD@85%\W
MD<T5$'FS$#R%20"#N>.?N4O;C89.9.<;R*SVR/`+9>1Z5$<48J\DC>2H"?,T
M4$C71[V_G3=]=I9]]E?%'8;;'H:R9Z;%96MP:[][2SJAG59J#;T$-?@L*)H[
M-XA!D)8_^.H/TS?Y0^ZMR?R]9C=?<:\^KF45=%D^GM(_DTA*R/0^>J,'^'KF
MQS_]]_W`YKW$['[1[?\`00.Q6.1HOJ[Z4>J0@/%%4?AT3,/XAT7.K^-/\V;Y
M$JV6W;@^^,O39"/[@CL7?E'L>@,:WIP!M[/;AP45!9.`IHXKQ\\KS['$7/GW
M<.23]-MLVSQ.AI_BUN;AO7^TCCD+?;K.?GU&LWMA][WW(!O-XM^8)HI!7_'+
MM;5*?#_8RS1!/L\-<9X=)>J^!W\R_JJ5\[A.O^TH*JGBE=Z_K+LK%YW)I'&I
MU+''M+=T^4F=U8Z(XD=WO95/LPC]X/8;F)1:7=[MYC)';=6KQK4^IFA"`>I)
M`'F>BJ7V`^]!RDQO[#;MV65027L;U)7`'H+>X,A/H%!)\ATH^N/YGGSQ^-&X
MH]K=D97+[RI\8XCR&P>]=MUM'N!((E%.4I\])2XG=]&T:Q^AY)*F'4+E'N;H
M=]]@/9_GRQ.X;''%:O(*K<;?*K1U.<Q@O"U:Y`"M3@1T9\L_>G]__:_<AM/,
MTLU['$:/:;I"RS`#%!*5CN%(I@DNM14J<];!GPV_F2=&?+R*GVY23MUSV\E,
MTU9UGN:M@:HR(A4&HJ]FYH)3T>Z*-!ZFC18JZ)06D@"#6<+O='V*YN]M&:^D
M'UW+):BW42FBUX">/+1-Y`DF,G`<DTZZ*^RGWFN0O>-%VR%CMO.06K64["KT
MXM;2T59U'$J`LJBI:,*-75A_N$NLC^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@E[S[
MJV-\>NK-W=N]BY`T&V=HXYJN:.'0V0RU?*ZT^+P6'IW=/N\OF*Z1(((P?U-J
M8A%9@).4>5=WYUYAMN6MC37N%R]`3\**,O(Y\D1068^@H*D@$'\^\\;#[<\I
MWG./,DGA[79QZB!37(YPD48--4DCD*H]34T4$C6'V;UA\A/YM?;>X^]^X]S_
M`.BSXY;%J*ZGJ,]43+%MO9FWL<K9"KVGL.FR,D>.KL_#CR),OF:C]F%F+S%K
M14WO/W=.8.2ONW<MP<H<KV_[QYXO%4B,"LL\C=HFN"H++&6Q#`O<PPH'=)UR
MRV7E7W&^^!SA<\_\Z7?[I]M-O9P92:0VT*=[6]HKD(TH2C7%R_:I.IR:)%T)
MU)\IL5LG.U?QL_E%_'N+-YA%>CSW?-7MQ]W;TW'*FFEJLY1U><C2GH<$'C)7
M(YF6.@8$F"CB32S$$GMY<;K9KSW]Y7>C%:GNCV]9?!@B'$1D1FK29S%`#)_'
M*QJ`*8?=BTV/<']L?N=\N">]`*R[JT)N+F8_"TJM**)%C$URPB-28X46A(.]
MH_'#O;+5M97?-C^8?UCUKN::.5JK8FX^U=Q=A[GH-$K3_9U6R-DS4N&Q<"^8
MM%#3!P+Z42P]B?E_GGE"VB2+VIY)W"_L`12XBM(K:)L4U"><%W.,LU/4FO0+
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M'^2V^_B-T#N[L*O[/V)B,SE,)FMY[(.W-J]NX;:#TE'NG/\`7V2ARF2J9(J"
M:H$W@RE/C*FHIM4T$4D:.5YL2,KR,ZC2I)('H">'Y<.NPL2-'$J.VMU4`MPJ
M0,FGSX]76>Z=.=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6O3_,:R&[_F?\T>GO@/L'(ST>U=
MH-1[S[3R=(1-!C*_(T'\1K\M7QJWC:3:.R)U%&DA&NORX0@'2?>:WL=!MGM9
M[5[G[Q[R@?<;G5!:(<%E5M*HIXTFG!UD<(X2?7KG+]Y6XWGWM][]E^[YR]*T
M>TV>FYOG7(1W36\CCA6WM2/#!XRW`'ITZ_*;%YCN'LWKG^5#\2E7874G7^WL
M1E_D%N7$I'/1X/;D1I\C'BLS/&\;U\L2U$-;5QR2I)E<U70QS65)C[3>WEQ:
M\L;!??>,]R?\<YEO9W3;HGPTDIJI=!^$&A1"`1#!&[+DKTK]V+2]YSYHVS[H
M_L_3;^3]NMHY-WFC`*Q0BCB.0@C61599%+`SW,J*^%<]!YC8LEO#&[U^-OP/
MSN*^-OP]Z>:IH_DG\S,Q4BFS>_\`.XVA6+<GV.Z&DH:RO*Q*57[6>F617!$M
M+1O%',=SM;[9/:<]^\$,F^^YVYT;:]D05CMXV:L6J*C*N>.M6(IE9)0S*'+:
M.ZWFUOO;+V`GAY8]F=FU+O7,DATRW<J+2;3/56?%0-#H"""&B@9%<&M@],_'
M#)05\7Q>^"G=?SC:EJ!#7=]=P[ORO7'6^:RU/+HK*W;U)"^%H\MC*F61G(G`
MG"@$Z_4Q%&\\T\\P.C>X'-^U<I!EJNWV4*7-RB$=JRDZV1@,=O;]F!T#.7^1
M_;.XCD3VLY"WSGMD:C[KN-Q)9V<D@-&:%1X2R(222'HX`S7)Z;.TNJ>M]NXF
MJR'R4_E:]D]$[1>=36=M_''LO([HAVU3!#%]U6X*O?-;-DI4ED#%9VI`^@V+
M'CVHY>YCWV]N%AY$]PK#=]RIVV>YVJQ&4\:+(HCG!H*54/2OETCYLY1Y8VVT
M>Y]S?:C<]@V8MW;ALUZ\XA6E-31.9;8J":T<QUI@GATNOCOTOOC%QX7%;-[*
MV-\K?Y8N^7K\CVY4=D9:BVYC^CL%A<=-F=RYO=.(SN7HLUU/OS9>.I_NHZO%
MS)250`=U0,KJ'_<+G7EZWM;K>.8[6XY6]\-MBU6[P@L+NIHH255,5U:RY#B<
M:HQ7)H015[4>W'-EW>V7+_*-[:\[?=LWB;3=QW!"&PH-3EX'<3V5["*-&UL=
M$I([1J!`>=D_(OYC]-=T_!;8/\C#H;JCY5_RVNYMU-/WYW?M*M/<>%S&]JGL
M.;:G:6$[`[0IMSR4_5=!LKKS$TE12UU3&B3S2-"JSF`4TF&G.G/',G/^\_OW
MF><3WPB6-:*J(B+4A510`!4LQ\R6))ZZ&>W?MKRA[5\O_P!6>2[8VVV&9I7U
M.TCR2N`"[NY+,=*JHX`*H`'5F_PC_D1?R\?Y??R9W_\`*_XZ;`WEBNT-[4.X
ML1BJ?<V^*[<>T^M,'NVL@K=Q8;KK"34U-+C:7(M3K#Y*^HR53!2W@AECC9U<
M)=#OJX[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7B;<G@#DD_CW[KW237?FR6I)*]=W;::AA6&2:M7-X
MTT<4-3]Q]O425(J?`E-4&DE"2EA&YC<`DJ;>Z]U2S_+">BW_`-J_._YM9U5J
M!N'?N9VYMK+,IBI$VGADFW1E5II)GF:%&QT.'1@#:-8`.18#+OW_`!+LW+O)
M_M19U4P6:2RIQ;QGI$E0*5[C,1ZEO7K`G[K#0<P\V\_^^=_1A<[A+##)2BBW
MCK/(`230:!;@^@7TX`;U%+O3;OP.[;[\P_F7Y#_S&>^CL#:^:FT_?XG&]B;T
MR&T<7%#4Z8ZJ*CQV,_C%7&T1*J9(66RHND6\RKM=][P;;R==4_J3R/L_U$L8
M^%VMH%F<D<"S-X*$'C1P<DU`O)S[WMOL%N_N#::A[C^Y/,'TD$C?'&EW<O;H
M`U`P54^ID4KPU1D4"@@;.PNJ^N-OTL7QW.)R>1^)7P=VKL3*=@;!P#I3Y7Y0
M?*+L%Z:LV#USEI86OE$JZW(T=96P-Z7KLO#%(HAC4QA39.8M]O9#SL)(T]R.
M;;BX2VN),IM6TVU5N+E`?@HJNB,,B.%F4EF(8<<Q\J<L[?$/;@PRR^T/(EI:
MR7=K%17WS?+PJUI9R$?VFIGCDD4X,MPB,`B@H;C;OP<K.W\5C=P?,#=F?W'7
M34M.V+^/G6NZ<UL#X^=48D%7H]FX;;^SZS#S[SJ<;2K'3U63R$LBU+H1%$D0
MC]QK?>[<7+-S)9>V5M#!"&.O<;J)+C<;Q_Q3O),KB`,:LD48&D'N8L3U,.W>
MP\O.5I%N/O)=W%S.R+X>T64\EIM%A'Q6VBAMVC-RR*`CS2L0Y!"J$"],F[?Y
M>>Q^J:2HWO\`%7MO=OQ;W/C9XYY*7([MR^[NC<]25-3#%48+??7N\LM5XNJP
M^1UK"/#-`ZNP(#-;V[:>^>X;R/H/<VPL]]VEEIK\*.WO8B!VR0742JRNISW!
M@>&!TQ>_=HVGEX_O/V;W._Y:WM'KX0FENMNG4D:XKFRG=U:-QCM*Z>-">@XP
MG2>=[CWA7]?=#[!V%TI\/(^U?DGTI_,;Z:[<^/.[=DYOY7RY;K7#[8QVY_CW
MG'R:04W4]=7YR<096D>GI:RG$BT[L8'CDBKF3FO?N:IX9=\N[F[6VB\&#QGU
MO'""2J%J#4<]S'+')ZG#E'DCECDFUGAY;L+2Q>\F\>X%O'X:23L`'<)4A%-.
MU%[5!H!QJ=KX;?"WXY?`7H[$?'7XL["_T=]5X;-9W<<.&FSV?W/D:W/[DJEJ
MLQF,MG]SY++9K)UU5XHHPTL["."&.-`J(H`<Z%W1J/?NO=4]_)'^=M\1NB^Z
M-P_&?K?:OR"^:'R2V<5CWSTQ\+^HLKW;GNO:N2>*F3']@[AI*O$[)VED1/(8
MY:>HR7GI)4,=2D+V!]U[I)YK^=YU?L_XV]Y?)/LGX8?S`NJ<5\:<SU]1=V]>
M=E_'VEVAV#M?;O8F2R^(HM_X*GR>\8]L[]V1MROQ.C-5F'R56<8D\<DJ"(M(
MONO=6V;$[9ZY[*ZKVKW;LO>&#S756]-D8KL?;N^8<A3Q[?K=DYC#1;@HMPOD
M9I$IZ;'_`,(F$TKR,HA4-KTE6M[KW1'_`(S_`,T[XP_);XS=M?-"DJ]R=/?$
M_JS>.]-L0=[]X08+8NR>PL+L3(G#YCL38DO\=R5=7[%K,U_D-!/50TM775X>
MFBIS.AC]^Z]T3&B_X4#]);YCJ=U?'_X,_P`SCY,=)T(:HG^0/3GQ$S]=UAD<
M2*R2C7.[3?=.?VONO>6*E>(E6Q^,EEM^J-??NO='<W7_`#-.B-H=P_`'I/*;
M6[;AW9_,:P6Z]P=)_?;.@P:[6I-G[&QF_P#*4?:^,SV7QNX-G9E<3E8X31K1
MU51#6*\4JQZ&(]U[JQ;W[KW56W\S?^;I\6_Y4N`ZFS/R)H.R=S5_<F:W/C]J
M[5ZGV]B-T[HAPNQ\339G>F\\IB\GN';YI]J[8I*^F^ZJ(VE96G7TV#%?=>ZL
MCV5O';G8FS=I=@;/R=/F]H[YVQ@=X[6S-*P>ER^W-S8JDS6$R=,X)#4]?C*V
M*5#^5<>_=>ZK&^6W\Y+XC?%'M_\`V6REQW=?R=^4,>*7-9#XY_$?J?/]X]F;
M:QLR4TE)5;VBPAI=N;+%7%5QR+%D<A!4I`ZSO$L+I(WNO=._QV_FG;/[TB[L
MH=X_$WYM_%[=_0W5&=[FW;M/Y,=%/U^V:V9M^D6JK3L?=-%N+/;+W7EP'"_:
MP9`2(3=](#%?=>Z(OUK_`,*.NJ>YMBX?L[J#^6]_-;[1Z\W#%6S;?WML+XIT
M>Z=K9U,=65.-KSB,YB.P*K'9`4F1HY:>0Q2,%FC9;W!]^Z]U8OW)_,SZ4Z*[
MQ^`_Q[[`V3V[C>Q?YAG\8BZFH#MG$P1[(K\#AMIYG+8KM>.NW#1U^V\I0KO"
MGIY8:6&O=*B*96L$N?=>Z/MO#;R[NVENG:CUU1C%W/MS-[>;)4@!J\>N:QE5
MC374H9E!J*05/D2Y`U*.??NO=58_\-K;E:4Y-^X=PQY*'>HWO!BH<_D1MBJF
MJ<PV8J^OLC0MC2[]#T$M+"E%M5`)ECJ:J-\@8V0#W7N@M_E=;.R<'\O7Y%;"
M^W%/NQ-^?(':.1I-;:Z?<2;%PN$6FD)*A&BE5%XT\"_U]Y:?>"W2W?WJV/>:
MZMM-GMTRMZQ?4/)4?:*]8(?=3V6Z3[N7,O+^G3NXW#=[=UKPF%K%%0^E#0>7
M6?J;"QU?Q8_E!YF'Q_P';_<&PCE#6O$BKD,KL'LW'8PZ&(1Y!N61!#P6$A2W
MJ(]TYCNC%[A>YEJU?K)MLN-&FOPI<6K/_P!4JZOE7RZ4\JV:S^U?L]?"GT,&
M]6OB:B`!)):WJH17C^OA/.I7SZ,MA=LP2;ZWBV4@A%+'_,7HMP[E&0C$;3Z>
MC=M-UO-$[0B26*'<DF%-*20IJ%TJ3:Q`EW?N-HM1;D^(>1VCBTYI_C\OU0.:
M`F(3Z_/2:D=258[7&V_WINU7PA[E+-/K%*_[JX/HB#2I`F-MX>::Q0$\.K)O
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M`QFZMD[XV[F=I;NVSF:9:S$;@VWN''U&)S>&R5*_IGH<ECJN2&5?RCGW[KW6
MC-7;'^;/2O86]_\`A+7UIDL]%U-WKV`>S^G?EA49^.HW!U9_*^WG/N#='='7
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M,_GL'!2Y;?'8^/RS_*OL+`05U3$#DL6]4V#IZY"4FI*F(Q,3&6'NO="__(7^
M2^]=N_`/Y(_$;?\`71[U^07\J/?G<7QZKJ6GK:;(3[UV!LJ'<.XNBL]CIL?-
MD%J<)F\#1R8;'O'KU08E>"2+^Z]TT_\`"5G8^W,O_+;K/EQF8_X_\B/F)W]W
MSV7W_P!CY=XJ_=FX]PX3M+<^T</B*S*.IKXL-C<=AOO(:-VT1U>1J9E`$P]^
MZ]U>]\MO^R5/DU_XKYW/_P"^XW)[]U[K49_D:?S`/YA'3/\`*W^+76_3G\G/
MN[Y-]:[=Q78,>U^\-J_(WIC8^`WQ35W:^^,E75.-VONNF?.XQ,3E:RHH'$Q_
M<EI6=?2P]^Z]T<+^<#5U=?\`SG_^$X-=7XZ7$5U;VK\@JNMQ,\T51/BZNHP_
M3TU1CIJB#]F>6BF<Q,Z>EBMQP??NO=;4_OW7NO>_=>ZK3^)5+'U!\KOFI\=*
MU4H\;N;=>"^3/6V.*:*6NVMV3CX\/O9Z*)TLZ8G>.+6GF]3W+@V'(]SQ[D2-
MS-[<\J\\15:>WMI-KNF\UEM6UP:B/XX7++@<#UC%[01)R;[M\[^VTP$=M=7<
M6]V:?A>"\41W)4'RCN$$;9-2:XSTENL.KLBW67R&^%=/6P8KL#HOLH]L]`Y"
MO-HI=I;@WDW<?2N=B+DZL7A=[4E9M[(F$:8$HW0!=:K[,>8.8(!O^R>ZKH9-
MFW>P^CW%5XB:.'Z*^C/].2`I<QU^(N#FA/1/RKRI<GE;F/V/B=8>8=@W3]X;
M2[\#;S7/[QVR45_T.*Y62SFTX41LM!4#H8HL]A]Y8NK[G&,R6+V1V+AL=M;Y
M`X*!6@WATCVKUI4O%C-ZU%%]I+5#([&RD7V&5D*$Q4M%C<@BR4<,C,%VL[K:
M[A>5O$CDW:QE:7;I#F"_M+H5>`-4#3<(?$A%<O)/"2LK*`-%W"RWJT?G;PI8
MMBW*!(-WB&+C;+^R:B7)726UVL@\*<T.E([6Y4-`C$F>P6_*ZBH*2/>-'-5:
MX(9*#>NT\?69_:&ZJ*44RTF7I&PJ9.IPDU?]PK-2U`,2FYAGGC&L`"\V>*69
MFVQ@M"=4$S+'-"PK5#XF@2!:4#KDXU(C&G4J6&_SP6Z+O2,]5!2YMT::WG4Z
M=,B^$':(O4$H_:,Z))%&KITJ-_PU,IH=KX#<.Y<GY_`R?PG)8'$495HO+/D<
M_G*&CH(:>*.77:#[F>0*1'$Y!`3ILS(OC;A-!!;TK\:R.W&@6.-F8DD4[M*C
M\3`=*Y.8DE?P-JM[FZNM5/[-XHUX5+RRJJ``&O;K9J456/2PQN8Q69BJ)L1D
MZ#*0TE;4XVJFQU93UL-/D*)_%64,TM/)(D=722^B6,D/&X*L`01[+)[:XM65
M+F-XV90P#*5)5LJP!I@C(/`C(Z.;6]M+U&>SECE1'9&*,&`=31E)!(#*<,.(
M.#GIQ]L=*>FG/X+#[IP6:VSN+'4N8V_N/$Y'!9W$5T0FH<KA\O1S8_)XZLA;
MB6EKJ*H>*13PR,1[]U[K6*Z&^)?\V_\`DR3[[Z3^"_5W5'\Q7^7]D]W;CWUT
MOT_V'W+CNB/D3\?7W5F/XKFMCT&]=T8ZIV7O':_W=5--&9/W*FI9ZFU$\LT<
MONO=7-_"'N3YW=R4?8F9^:GPZV5\/*>CJ=MIU7M;;_?^W.^=S[AI*E<ZVZ*K
M>5=M+$8[;^WI<<T6.6EA@DJ#,99RS`(E_=>Z(WO?X=?(K+_\*$>E_F_C]@"?
MXQ[3^`&Z^E,]V/\`WEVK&:'LO);XW9F*/;IVK+F4W?4>;'Y."0545"](-9!E
M#*1[]U[HR/\`-B_EL8C^99\>=O[$P_8>0Z4[]Z6[%P'>/QD[QQ5,]95=:=O[
M2\K8FKR-'"\-57;;RT4AAK(X766&5(*J,/)3)$_NO=$FVE\J/^%$'5^!Q/6_
M9W\K;XZ?)G?6*H8\5+\@^JOFAL3J;KK>%312-2_WGS?7N]=O2[JVY/E::):B
M:"DA$1GD;QP4T>F)/=>Z"_\`F?=&?S+-Y_)[^3Q\WNB_AOMOY`]H_$G`]T[E
M[_Z;VWWML'K[:^"WWVKUWL_;$^V,#OSL.OQM3E\/CLK/DFIJZ"@J#-'0+Y8X
M_,MO=>Z-+L_Y?_SDNRNKOE!3[P_E/TGQU[%V[\>-ZYKXX5T/R[Z1[63L'ORH
MJ,;@]E[,K:'&SX&CV[C:5<M/F*FOK:J.F\&,>`7EFC!]U[HN_P`'/^$VO\O'
M:'Q-Z,Q?S,^)^Q.X_E?6;(H]S?(;L+=.Z=Z93,9?MG>$]3NG>./ER.!WC286
MOI=L97+OBJ>>FC$51!1+-=WD9V]U[J9T+_*YW5_+@_G`;6[/^!W0&.V[_+P^
M3OQJK>L?E%M;`;NPL>*ZF[8V)D,WG.O]]4FWMY[K?=^X*3<!--0R+0QUOVW\
M1KY6"J50^Z]TA^O/@_\`S.?Y/W:W=2_RS=@=._-#X)=Z=A;A[@I_B/VAV?\`
MZ#^T_C]V!N(TRYF@ZI[#S5/D=FY/961CBB415BF4PT<,9ACG66MJ_=>Z/UUA
MV?\`S./E)UA\IMG_`"=^`VP_B/MK</QX[%VUU'C*3Y.;,[M[#WGV5N/;F1PM
M#B,TFT\;C-H[7P<D-<UJB6K<^8+J*H6(]U[JG[^6IO/^>M_+L^%'2WP\I?Y*
MM!VM'T]0[KHX]_2?.SX][1?<']YM[[DWF)9-O?<[@&.>C.X?MB%JY0XAU\:K
M#W7NA_\`YNOQV_F*]O\`RC_DW_-WXT?#2#NC>7Q(3LWL?NWI*3O/J_8D>UMX
M;\PG4KQ;!&^]UY:@H\RM#D,9E*<9''TE9`YH0Y15F2_NO=61_"[Y7_S.NZ>X
MJC9_R[_E=T?P^ZHCV;F\S!VU!\L^J.ZY)]VT5;AX,/M'^YNRZ2',1KF:.LJY
MOO2WA@^TTMS(OOW7NK8/?NO=$1^9'7^\<'D^M_EKU#B*O.]G?'B;)MN/:.,5
MFR':'1^X%B'8NQ::%5;[O-44%.F5Q"L#:MIBJ#7(/<O^U^];9=V]][;<RRK#
ML&]A/"F;X;2_CK]-<$^2,28IC_`P)PO4!^]/+N\V%UMGN_R="]QS3RXS^-;I
M\=]MDM/K+51^*50!/;@UI(A`&IAT_;PQ=/WSMWJWY8_%W<>#R78>W,%4UVRZ
MNIJS2;;[2V%G?%/N?I[?51`LTV+AKZRD5J>>1'FP.=IDE:,A:B-T>V7#\GWN
MX>W'N#!,FR3S!9P!66TN(ZB*]MP:!RJDAE!"W%NQ4-E&"[>K2/G_`&[:O=WV
MJN8)>9+:W9K9F;3#?6DM#/MUT14H'9048@M:72!RM!(K0=FYBA[5RV:[9Z%R
M<?77=%&,?AN\ND.QJ2>@3(Y/&TYIZ3$=E8&B:3);=W/0T\9BQ&[,:E5!6T*H
M-.0I%A2)[=+:;EVVBY;YQC-]RJVI["_MB&TJQJ7M9&HLL3',UG*49)"36"0L
M68V6]@YMO)^;_;^4;;SNFB/=-KO%*!W046.]B6KPSH!IM]PA$BRQ`"ES"$5'
M*BRNWMJ3U$^5VAW3\>\A%)+E,Q2;1P]=O?JVMR%9(@GJZ%]L8;>NT`M3-,79
MFH<153,6>:(,/;$MO>[BBI;W.U;U"0$0S.L%VJJ,!O%>";`%!^I,BB@1J=*8
M+O;MHD:2[L]\Y<N`3)(MO&UU8L[$59#!'<V_<34GPK>1C4N@(ZC5N]MA;KIY
M4?=/R'[JC#FAJ-J;1V1N;;V)R`J/((X\E6X+:/7^%-(&B*,U9E8Z5M0$MU/N
M\6T[SMS@BWV3:FIJ$TT\4CK3S59)KAZYJ`D)?S7/3<^^<O;O$0UWS)OBUTFW
MM[6>&-ZUH':*WM(M.*$R3JAK1ZCH2MJ5N]L#!_>O>]/LCH#IK9>)KS2;"2JP
M-15KCTAT1YC>^ZH6@VIM+'XU2TD>.Q1J!Y&#S5[@&#V1;C%M-X_[NVEKO>>:
M+N1:W%)`-5<I!":S3,^`99M.*A80>_H3;1/OEA'^]]]6QY=Y)L87TVFJ(MHI
MB2ZG%+>W1,L(8->2"]P16/H9MG[NP&_=LX?>&U:R7([=S])]_A\A+09'&&NH
M6DDCAK(Z/*TE#7)35(CUPN\2B6)ED2Z,K$+;GME[L]_+MFXJ$OH6TNH97TM0
M$J60LM16C`$T-0:$$=#?9MXV[F#:X=YVES+MMPFN-RCIK6I`8+(JMI:E5)4:
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MJ%)2*JK#57QI^8;P[QV;N+*;?[:V9`V,JLOMROR'67R!ZS=G5JG;>[L/.E+G
MZ?'I4RE7Q^7I*S#U#EF1)0VLEUU'SY[8@[9ND$<W+=T=0255NMNNO26%Q6,L
M0,20NDRB@)4BG1K92^V'O.R[ULMS+;\WV2Z&DA=[+=K+.8;B,A90@8T,-Q')
M;N:D*X-2NJ?;/RGVJ@I<1V;U?VG01B5HINRME939FZ6_0M/3U>>Z\KY=N5&E
M5+/-'@("[-8(`.2A[_V\W$^)<V&X;=,:5%K.D\/S(CN5$H^2FX:@\ST?Q[7[
ML[2/"L]UVK=K<5H;VV>VG^0:6S<PGU+"T6I/PCKJ:#Y@94"F6N^.FRHW81S9
M2EI.Q^P:V.&0,LD]%CZR3KZBCJZ>X:,323Q.19@![\C^V5L?$*;Y=D9"$VUL
MI/D&9?J6(/`Z0I'D>M21^\UV/"$G+5BIP9%6\NV`/$JC&T4,.(U,RGS'2<K.
MA-GX]1V-\H.V,AVTNUY(LTDO957@=E]+[1JJ-@]-EZ+KC'''[,CJJ%S^Q6YE
M\K60FS+.'&KVNBYQW.<_N/V_VU-M-P"E+59)[Z8-Q1KEM4Y#?B2`0HW`I3'1
M9-[?;-;#^LONKN\F\"T(E!O6BMMMMV7*R+9IHM@RGX9+DSR*:$2:L]<=C_)'
M<7>6_L/1]#;(;-](XNLF;>_?6\(\E@MJ[@AA@GC3`],8QHJ?*[YKGKFB,N99
M(L'#"DBQR5,C*!O=^1;+E+9I9><+OPN;)%'@;?"5DFC)(/B7SU*6ZZ:T@!,[
M$@LL:@]>V'W,W+GSF"&'V_L#/R+$Y^JW:X#Q03``CPMM2@DNG+:=5R0MJJA@
MK2L10WGN-.ICZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB(?+#_9,/XU
M@_\`39]M_IA\0_N3_HO_`+T?[,7:\?@_NS_HK_XR-_#]>FWF_P!QM_U\7]S!
M[<_ZZ?TLW]5-7]6*_K_5^%^[?.OB_5_XMJ_TOZOIU`'N[_K(_70?UYT?UTI_
MBOT/C_OCY>!]!_CFC_3?H_Q=%TI?]GD^TE_T#?[-#_=K3!_!_P#9G_\`9:/X
MI]9+?<?Q#_C)'V.FVO\`B'^7Z?U>OV-Y/]:/Q!_7#^K_`-?4Z_W5^]-'EPT_
MXKJ]/#_3KPQU&\7^OQX)_J!_6O\`=F/#_?G[DU^?Q:_\=T^OC?JTXYZPUW_#
MJ7AK?[R_Q3^%_8FW^A[_`&7#^]'E\PU_:_Z0?\A^X\/Z-/'UOS;W>'_@>-2?
M0>']1K_XF_O/PJ4\_INZE>->F[C_`(++0_[S\;Z3P_\`EG?N;QZU_#]7VUIP
MI\^HFT?]D_\`[_8/_9L?]F"_TK?Q&/\`NY_L]7\3_N1_%OO)OM_[H_PO_G&_
M5]U?[7P?N_H\?JM[<W+_`%S?W--_K<?N7^KF@^+^X-'CZ-(KXVO_`'9\/CU8
MXZL5Z9V?_69_K#!_KO?UC_K=X@\'^M.OZ7Q-1I]/X?\`NE^+X-/=PTYIU<%1
M_9_9TO\`#_MOL/MH/L?L_%]G]GXE^V^U\'[/VWATZ-'ITVMQ[QEE\7Q6\?5X
MVHZM5=6JN:US6O&N:\>LS(/!\%/IM/T^D:=--.FG;IIC32E*8IPZD^V^G>O>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
4KWOW7NO>_=>Z][]U[KWOW7NO_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`%P)-`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
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M?5N8EK-F;"K*R#.9"HBK\JU/64\5+D\27CH7`>4^93H'Y^GOW7NK-,!24V/P
M6%H**EJ:*CHL3CJ2DHJQWDK*2FIJ.&&"EJY)))I)*FGB0)(S.S%@223S[]U[
MIV]^Z]U71\T:+,T>^.NMX;XVQN[>WQSP.(S"[WPFS<E64-3B-P5$A2BW-EHL
M?54=344E#3LAC)D2-65@65F%_=>Z/'USD]KYC86S\GLFLDK]I5>WL6^WJN>:
MIJ*B;%+21QTIJ9JQGJY*I(TTRF0E_(#JY]^Z]TM/?NO=$/\`FYBMY5%-UGG5
MV]N3>G3NVL[D<CVYL_:-?4T&8R6.%+$,=6SFCF@JZC&8TK,[JK!5:VLJ#J7W
M7NC*=$YK8&X.I]F9+J^HKI]COC6BPBY.HK*K)TD<%3/'44&0FR$]36&KH:I7
MB8/(]M-@Q6Q]^Z]T+GOW7NO>_=>Z][]U[KWOW7NJKOE-F>OZ7Y38B'N*HS%1
MUKC.CLIEI,=13YTQ4N?.6KZ?&9&GI\+*CTU>9RJ).^F)7TZV`M[]U[HX/Q,Q
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MJIJ60T-.`2-3U-:8XU'Y+#W[KW1`/A#G\QM+L#='6>Y]RQ[AK.P=A[4[GQ]1
M_%(LE]IF<O"PW5@U:.HG$$U%+51EHN"HC)('OW7NK//?NO=>]^Z]U5IM"6@V
M3\J<RGR,PF\HM[[K[$J:GI3LA<QE1L>KPKQ/38?:D-+25D6.AC2&95:*6*2T
MK*)`A`9O=>ZM+]^Z]U[W[KW53V4QN%W)\X^U<7NG9O86_:&A7KF?#P;-KLA'
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M&X[]HPS8J=(U5UD!9M*DGCW[KW1RX$DCAA2:7SS)%&DL^A8O-(J`22^)/1'Y
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MP5%DJ:NJF=VLJJ+V```'OW7NE_[]U[KWOW7NO>_=>Z][]U[HO.]OCCM+?_9T
M_9&XLA7U25O6F8ZPR&V#!2-BJO$9F6HEFK6F>-JI*Z!Y[QD'2K(K?4>_=>Z7
M'3W6[]2;`PO7Z[HR^[:';RSTN)R><BI8\C!BFE:2CQDKTBI'/%CT8QQN1J\8
M"GA1[]U[H3O?NO=`UWOTSB^^-A/L+,9K)8"D?,XG-#(XF*EFJTGQ$SSP1JE8
MDD)21W]7%^/?NO=*/K?9V?V1@IL1N'?^?[%JFK6J*?,;BH\115E)2>""&+&Q
M1X:DHZ=J>$PE@S*7)<W)X]^Z]T(7OW7N@I[KZHQG=G7.<ZXR^5K\+C\X^/>?
M(XV.GEK(?X?7T]>BQ)5(\!$KTX5KCZ$V]^Z]U*ZLV%FNNMOM@,QV!N#L%8I8
M%QE;N&CQ%'48K&TM'3T=/BJ9,124D4E-$L&H-(&D)8W)]^Z]T)GOW7N@N[FZ
MMQO='7&X>M\ODZ[#X_<4=''49'&QP2UD`HZZFKE\*5*M"?(],%-Q]"?S[]U[
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M+IU(XX92#[]U[J/_`*=*3_GU?>7_`**_-?\`1_OW7NO?Z=*3_GU?>7_HK\U_
MT?[]U[KW^G2D_P"?5]Y?^BOS7_1_OW7NO?Z=*3_GU?>7_HK\U_T?[]U[KW^G
M2D_Y]7WE_P"BOS7_`$?[]U[KW^G2D_Y]7WE_Z*_-?]'^_=>Z]_ITI/\`GU?>
M7_HK\U_T?[]U[KW^G2D_Y]7WE_Z*_-?]'^_=>Z]_ITI/^?5]Y?\`HK\U_P!'
M^_=>Z]_ITI/^?5]Y?^BOS7_1_OW7NO?Z=*3_`)]7WE_Z*_-?]'^_=>Z]_ITI
M/^?5]Y?^BOS7_1_OW7NO?Z=*3_GU?>7_`**_-?\`1_OW7NO?Z=*3_GU?>7_H
MK\U_T?[]U[KW^G2D_P"?5]Y?^BOS7_1_OW7NO?Z=*3_GU?>7_HK\U_T?[]U[
MKW^G2D_Y]7WE_P"BOS7_`$?[]U[KW^G2D_Y]7WE_Z*_-?]'^_=>Z]_ITI/\`
MGU?>7_HK\U_T?[]U[KW^G2D_Y]7WE_Z*_-?]'^_=>Z]_ITI/^?5]Y?\`HK\U
M_P!'^_=>Z]_ITI/^?5]Y?^BOS7_1_OW7NO?Z=*3_`)]7WE_Z*_-?]'^_=>Z]
M_ITI/^?5]Y?^BOS7_1_OW7NO?Z=*3_GU?>7_`**_-?\`1_OW7NO?Z=*3_GU?
M>7_HK\U_T?[]U[KW^G2D_P"?5]Y?^BOS7_1_OW7NO?Z=*3_GU?>7_HK\U_T?
M[]U[KW^G2D_Y]7WE_P"BOS7_`$?[]U[KW^G2D_Y]7WE_Z*_-?]'^_=>Z]_IT
MI/\`GU?>7_HK\U_T?[]U[KW^G2D_Y]7WE_Z*_-?]'^_=>Z]_ITI/^?5]Y?\`
MHK\U_P!'^_=>Z]_ITI/^?5]Y?^BOS7_1_OW7NO?Z=*3_`)]7WE_Z*_-?]'^_
M=>Z]_ITI/^?5]Y?^BOS7_1_OW7NO?Z=*3_GU?>7_`**_-?\`1_OW7NO?Z=*3
M_GU?>7_HK\U_T?[]U[KW^G2D_P"?5]Y?^BOS7_1_OW7NO?Z=*3_GU?>7_HK\
MU_T?[]U[KW^G2D_Y]7WE_P"BOS7_`$?[]U[KW^G2D_Y]7WE_Z*_-?]'^_=>Z
M]_ITI/\`GU?>7_HK\U_T?[]U[KW^G2D_Y]7WE_Z*_-?]'^_=>Z]_ITI/^?5]
MY?\`HK\U_P!'^_=>Z]_ITI/^?5]Y?^BOS7_1_OW7NO?Z=*3_`)]7WE_Z*_-?
M]'^_=>Z]_ITI/^?5]Y?^BOS7_1_OW7NO?Z=*3_GU?>7_`**_-?\`1_OW7NO?
MZ=*3_GU?>7_HK\U_T?[]U[KW^G2D_P"?5]Y?^BOS7_1_OW7NO?Z=*3_GU?>7
M_HK\U_T?[]U[KW^G2D_Y]7WE_P"BOS7_`$?[]U[KW^G2D_Y]7WE_Z*_-?]'^
M_=>Z]_ITI/\`GU?>7_HK\U_T?[]U[KW^G2D_Y]7WE_Z*_-?]'^_=>Z]_ITI/
M^?5]Y?\`HK\U_P!'^_=>Z]_ITI/^?5]Y?^BOS7_1_OW7NO?Z=*3_`)]7WE_Z
M*_-?]'^_=>Z]_ITI/^?5]Y?^BOS7_1_OW7NO?Z=*3_GU?>7_`**_-?\`1_OW
M7NO?Z=*3_GU?>7_HK\U_T?[]U[KW^G2D_P"?5]Y?^BOS7_1_OW7NO?Z=*3_G
MU?>7_HK\U_T?[]U[KW^G2D_Y]7WE_P"BOS7_`$?[]U[KW^G2D_Y]7WE_Z*_-
M?]'^_=>Z]_ITI/\`GU?>7_HK\U_T?[]U[KW^G2D_Y]7WE_Z*_-?]'^_=>Z]_
MITI/^?5]Y?\`HK\U_P!'^_=>Z]_ITI/^?5]Y?^BOS7_1_OW7NO?Z=*3_`)]7
MWE_Z*_-?]'^_=>Z]_ITI/^?5]Y?^BOS7_1_OW7NN8[PI3'))_HN[O`C>%-!Z
9QS(D?S+.VJ--=W2/P6<_V2R_ZKW[KW7_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
